10-K: ImmuCell Reports Increased Sales, Awaits FDA Decision on Re-Tain

ImmuCell Corporation's 10-K filing reveals a significant increase in First Defense product sales and provides updates on the regulatory pathway for Re-Tain, its novel mastitis treatment.

Summary

• ImmuCell Corporation's 10-K filing highlights a 52% increase in product sales, reaching $26.5 million for the year ended December 31, 2024, driven primarily by the First Defense product line.
• The company is awaiting FDA approval for Re-Tain, a purified Nisin treatment for subclinical mastitis, and has submitted its fourth submission of the final Technical Section in January 2025.
• ImmuCell experienced production contamination events between 2022 and 2024, resulting in charges to costs of goods sold of approximately $407,000 and $527,000 during 2024 and 2023, respectively, but has been operating without new events since April 2024.
• The company estimates the total U.S. market for scours preventative products is approximately $31.1 million per year for calf-level products and $81.8 million per year when including dam-level products.
• ImmuCell's share of the calf-level scour preventative market was approximately 48% in 2024, while its share of the combined calf and dam-level market was approximately 15%.
• The company is implementing a Controlled Launch strategy for Re-Tain, focusing on early adopters and careful market introduction.
• Product development spending on Re-Tain totaled approximately $30.2 million between 2000 and 2024.
• The company projects that existing cash and cash equivalents, along with gross margin from product sales, will be sufficient to fund operations for at least the next 12 months.
• The company is targeting to reduce product development expenses (excluding depreciation) to approximately $2.1 million during the year ending December 31, 2025.
• The company settled its business interruption insurance claim and received an insurance payout of approximately $427,000 during the first quarter of 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While sales are up and the company is working to improve gross margins, there are ongoing challenges with production, regulatory approvals, and debt covenants. The future outlook is cautiously optimistic.

Positives

• Significant increase in product sales, driven by the First Defense product line.
• Growing market share in the U.S. scour preventative market.
• Advancement in the regulatory process for Re-Tain, with the fourth submission of the final Technical Section made in January 2025.
• Successful remediation of production contamination events, with no new events since April 2024.
• Implementation of a Controlled Launch strategy for Re-Tain, focusing on early adopters and careful market introduction.
• Projected sufficiency of existing cash and cash equivalents, along with gross margin from product sales, to fund operations for at least the next 12 months.
• Targeted reduction in product development expenses (excluding depreciation) to approximately $2.1 million during the year ending December 31, 2025.
• Settlement of business interruption insurance claim and receipt of an insurance payout of approximately $427,000 during the first quarter of 2025.

Negatives

• Production contamination events between 2022 and 2024 impacted gross margins.
• Reliance on the First Defense product line for the majority of product sales.
• Concentration of sales with a small number of distributors.
• Debt covenants require meeting a minimum debt service coverage ratio, which has been waived in the past.
• The company experienced a net operating loss of $1.6 million during the year ended December 31, 2024.
• The company experienced a net loss of ($2.2 million), or ($0.26) per basic share, during the year ended December 31, 2024.

Risks

• Difficulties or delays in development, testing, regulatory approval, production and marketing of products.
• Competition within anticipated product markets.
• Customer acceptance of new and existing products.
• Alignment between manufacturing resources and product demand.
• Adverse impacts of supply chain disruptions on operations and customer and supplier relationships.
• Commercial and operational risks relating to current and planned expansion of production capacity.
• Exposure to interest rates and debt service obligations.
• Debt covenants may not be met.
• Inflation, supply disruptions, tax rates and economic downturns.
• Uncertainty of market size and product sales estimates.
• Reliance on sales of the First Defense product line.
• Production capacity constraints.
• Regulatory requirements for the First Defense product line and Re-Tain.
• Dependence on key personnel.
• Competition from others.
• Tariffs and trade policies.
• International conflicts.
• Climate change.
• Bovine diseases.
• Stock market valuation and liquidity.
• Possible dilution.

Future Outlook

The company projects that existing cash and cash equivalents, along with gross margin from product sales, will be sufficient to fund operations for at least the next 12 months and is targeting to reduce product development expenses (excluding depreciation) to approximately $2.1 million during the year ending December 31, 2025.

Management Comments

• The First Defense production capacity expansion that we initially thought might have been completed in a year to a year and a half ended up taking about three years to complete, but our fourth quarter sales results do demonstrate that we have increased our production capacity to, or above, $30 million per year.
• We did not find one smoking gun as the root cause to the contamination and yield losses.
• We think the solution is more about optimizing and controlling critical process parameters and multiple production inputs and process steps.
• After an investment of about 25 years and approximately $50 million in the development of this technology, we are committed to seeing this product through to regulatory approval and our previously disclosed limited distribution, controlled launch strategy (Controlled Launch).
• At the same time, we are also in the very early stages of exploring potential strategic options that could offset some of our product development expenses and enhance a mass-market launch of Re-Tain.

Industry Context

The animal health market is competitive, with ImmuCell competing against larger companies with greater resources. The company is focused on developing innovative products, such as Re-Tain, to differentiate itself and address unmet needs in the dairy and beef industries.

Comparison to Industry Standards

• The company competes with Zoetis, Merck, and Elanco in the animal health market.
• Zoetis sells Calf-Guard, a product that competes directly with the First Defense product line in preventing scours via oral delivery to newborn calves.
• Elanco, Merck and Zoetis provide dam vaccine products to the market.
• Boehringer Ingelheim, Merck and Zoetis are potential competitors with respect to Re-Tain.
• The mastitis products sold by these large companies are well established in the market and are priced lower than what we expect for Re-Tain, but all of them involve traditional antibiotics and are sold subject to a requirement to discard milk during and for a period of time after treatment (unlike our product which does not carry an FDA-required milk discard or pre-slaughter withdrawal period).

Related Party Transactions

• David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the First Defense product line and CMT).
• His affiliated company purchased $567,114 and $231,405 of products from us during the years ended December 31, 2024 and 2023, respectively, all on terms consistent with those offered to other distributors of similar status.
• Our accounts receivable (subject to standard and customary payment terms) due from this affiliated company aggregated $52,097 and $42,507 as of December 31, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders: The company's financial performance and future prospects impact shareholder value.
• Employees: The company's financial stability and growth affect employee job security and compensation.
• Customers: The availability and effectiveness of the company's products impact dairy and beef producers.
• Suppliers: The company's financial health affects its ability to pay suppliers.
• Creditors: The company's ability to meet debt obligations impacts creditors.

Next Steps

• Continue to pursue FDA approval for Re-Tain.
• Implement the Controlled Launch strategy for Re-Tain.
• Optimize production processes and improve yields for First Defense.
• Reduce product development expenses.
• Explore potential strategic options for Re-Tain.
• Continue to expand the First Defense product line.
• Investigate requirements to sell the First Defense product line in Mexico, Pakistan and India.

Key Dates

Keywords

ImmuCell, First Defense, Re-Tain, Mastitis, Scours, Animal Health, FDA, USDA, Nisin, Colostrum, Bacteriocin, Antibiotics